Castleark Management’s Krystal Biotech KRYS Stock Holding History

Castleark Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6M	Sell	16,150 -15,480	-49%	-$4.63M	0.16%	146
2026 Q1	$8.17M	Buy	31,630 +2,370	+8%	+$631K	0.27%	87
2025 Q4	$7.21M	Buy	+29,260	New	+$6.16M	0.21%	114
2025 Q2	–	Sell	-26,120	Closed	-$4.71M	–	310
2025 Q1	$4.71M	Buy	+26,120	New	+$4.39M	0.16%	129
2024 Q4	–	Sell	-27,290	Closed	-$4.97M	–	308
2024 Q3	$4.97M	Sell	27,290 -990	-4%	-$191K	0.2%	123
2024 Q2	$5.19M	Sell	28,280 -240	-0.8%	-$40.3K	0.21%	111
2024 Q1	$5.07M	Sell	28,520 -3,830	-12%	-$532K	0.21%	116
2023 Q4	$4.01M	Buy	32,350 +20,930	+183%	+$2.32M	0.18%	136
2023 Q3	$1.32M	Buy	+11,420	New	+$1.39M	0.07%	181

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Castleark Management's KRYS Position: Q2 2026 in Review

Castleark Management reduced its Krystal Biotech (KRYS) stake by 49% in Q2 2026, selling an estimated $4.63M and leaving 16,150 shares worth $6M. The position accounts for 0.16% of the portfolio, ranked #146.

Castleark Management first reported a position in KRYS in Q3 2023 and has held it in 9 quarters since. The position peaked at $8.17M in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Castleark Management held 16,150 shares of Krystal Biotech worth $6M as of Q2 2026.
Castleark Management sold 15,480 Krystal Biotech shares in Q2 2026, an estimated $4.63M.
Krystal Biotech made up 0.16% of Castleark Management's portfolio in Q2 2026, its #146 holding.
Castleark Management first reported a position in Krystal Biotech in Q3 2023 and has held it in 9 quarters since.
Castleark Management's Krystal Biotech position peaked at $8.17M in Q1 2026.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.